Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 24, 2014 - Issue 3
Submit an article Journal homepage
390
Views
4
CrossRef citations to date
0
Altmetric
Patent Evaluations

Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum

Peter NormanNorman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, [email protected]
, MBA PhD
Pages 361-368 | Published online: 03 Jan 2014

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Xingrui He, Xiabin Chen, Hancheng Zhang, Tian Xie & Xiang-Yang Ye. (2019) Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018). Expert Opinion on Therapeutic Patents 29:2, pages 137-149.
Read now
Michaela Prchal-Murphy, Agnieszka Witalisz-Siepracka, Karoline T Bednarik, Eva Maria Putz, Dagmar Gotthardt, Katrin Meissl, Veronika Sexl, Mathias Müller & Birgit Strobl. (2015) In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. OncoImmunology 4:11.
Read now

Articles from other publishers (2)

Kuojun Zhang, Ke Ye, He Tang, Zhihao Qi, Tianyu Wang, Jie Mao, Xiangyu Zhang & Sheng Jiang. (2023) Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors. Journal of Medicinal Chemistry 66:7, pages 4378-4416.
Crossref
Yusuke Sasaki, Hidekazu Tokuhara, Yusuke Ohba, Atsutoshi Okabe, Masaharu Nakayama, Hideyuki Nakagawa, Robert Skene, Isaac Hoffman, Hua Zou & Masato Yoshida. (2020) Efficient synthesis of tert-butyl 3-cyano-3-cyclopropyl-2-oxopyrrolidine-4-carboxylates: Highly functionalized 2-pyrrolidinone enabling access to novel macrocyclic Tyk2 inhibitors. Bioorganic & Medicinal Chemistry Letters 30:5, pages 126963.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.